Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis

Figure 2 Kaplan-Meier curves of progression-free survival and overall survival in the triple therapy group and angiogenesis inhibitors and programmed cell death protein 1/programmed cell death ligand 1 blockers group. A: Prior to propensity score matching (PSM), median progression-free survival (PFS) was 11.1 vs 6.0 mo, P < 0.001; B: Prior to PSM, median overall survival (OS) was not reached vs 11.8 mo, P < 0.001; C: Following PSM, median PFS was 12.5 vs 7.8 mo, P = 0.036; D: Following PSM, median OS was 31.6 vs 14.6 mo, P < 0.001. triple therapy: Hepatic arterial infusion chemotherapy plus angiogenesis inhibitors and programmed cell death protein 1/programmed cell death ligand 1 blockers; AIPB: Angiogenesis inhibitors and programmed cell death protein 1/programmed cell death ligand 1 blockers.